NCT02074839 2025-06-08Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 MutationServierPhase 1 Recruiting291 enrolled 3 FDA
NCT04955938 2024-07-31A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative NeoplasmsUniversity of ChicagoPhase 1 Withdrawn